SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RES INSTITUTE) has a total of 36 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2015. It filed its patents most often in Canada, WIPO (World Intellectual Property Organization) and Mexico. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are SEATTLE CHILDREN S HOSPITAL DBA SEATTLE CHILDREN S RES INST, CHENGDU HUACHUANG BIOTECHNOLOGY CO LTD and JCR PHARMACEUTICALS CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Mexico | 5 | |
#4 | United States | 5 | |
#5 | Australia | 3 | |
#6 | EPO (European Patent Office) | 3 | |
#7 | China | 1 | |
#8 | United Kingdom | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks | |
#4 | Measurement | |
#5 | Organic fine chemistry | |
#6 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds | |
#5 | Enzymes | |
#6 | Analysing materials | |
#7 | Climate change adaptation technologies | |
#8 | Combinatorial chemistry | |
#9 | Measuring microorganism processes | |
#10 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Jensen Michael C | 22 |
#2 | Michael C Jensen | 5 |
#3 | Scharenberg Andrew M | 4 |
#4 | Johnson Adam | 4 |
#5 | Crane Courtney | 3 |
#6 | Lu Yingjuan J | 2 |
#7 | Matthaei James F | 2 |
#8 | Jacoby Kyle | 2 |
#9 | Pun Suzie | 2 |
#10 | Gustafson Joshua | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020163634A1 | Chimeric cytokine receptors | |
WO2020160217A1 | Microenvironment sensors to regulate engineered gene expression | |
AU2019217363A1 | Closed-system manufacturing process for CAR-T cells | |
AU2019209432A1 | Methods of use for CAR T cells | |
WO2017044487A1 | Genetic engineering of macrophages for immunotherapy | |
US2016312210A1 | Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption | |
CA2963840A1 | Long poly(a) plasmids and methods for introduction of long poly(a) sequences into the plasmid | |
CA2945302A1 | Defined composition gene modified t-cell products | |
US2017029531A1 | Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells |